TET2突变作为骨髓增生异常综合征中DNA双加氧酶缺陷的一部分
研究收集1665例MDS患者和91例对照的DNA/RNA测序及5-hmC数据,发现部分MDS患者TET2表达降低而5-hmC水平并非一致下降,TET3在MDS中上调且与野生型病例TET2表达呈负相关,TET3低表达与TET2突变携带者不良预后相关。
要点
- 部分MDS患者TET2表达降低,但5-hmC水平并非一致下降。
- TET3在MDS中上调,在野生型病例中与TET2表达呈负相关。
- TET3代偿缺失(低TET3表达)与TET2突变携带者不良预后相关。
核心结论
- TET3水平升高影响TET2缺陷的临床表型,TET3代偿缺失(低TET3表达)与TET2突变携带者不良预后相关。
研究设计与样本
- 研究收集1665例MDS患者和91例对照的DNA/RNA测序及5-hmC数据。
主要发现
- 不论突变状态,相当一部分MDS患者TET2表达较低,而5-hmC水平并非一致下降。
- TET3在MDS中上调,在野生型病例中与TET2表达呈负相关。
- TET2在所有年龄组均降低,而TET3水平升高,可能为TET2功能障碍诱导的反馈机制。
- TET2与TET3表达的负相关关系也与L-2-羟基戊二酸脱氢酶表达相对应,该酶参与激动剂/拮抗剂底物代谢。
- TET3代偿缺失(低TET3表达)与TET2突变携带者不良预后相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Decrease in DNA dioxygenase activity generated by TET2 gene family is crucial in myelodysplastic syndromes (MDS). The general downregulation of 5-hydroxymethylcytosine (5-hmC) argues for a role of DNA demethylation in MDS beyond TET2 mutations, which albeit frequent, do not convey any prognostic significance. We investigated TETs expression to identify factors which can modulate the impact of mutations and thus 5-hmC levels on clinical phenotypes and prognosis of MDS patients. DNA/RNA-sequencing and 5-hmC data were collected from 1665 patients with MDS and 91 controls. Irrespective of mutations, a significant fraction of MDS patients exhibited lower TET2 expression, whereas 5-hmC levels were not uniformly decreased. In searching for factors explaining compensatory mechanisms, we discovered that TET3 was upregulated in MDS and inversely correlated with TET2 expression in wild-type cases. Although TET2 was reduced across all age groups, TET3 levels were increased in a likely feedback mechanism induced by TET2 dysfunction. This inverse relationship of TET2 and TET3 expression also corresponded to the expression of L-2-hydroxyglutarate dehydrogenase, involved in agonist/antagonist substrate metabolism. Importantly, elevated TET3 levels influenced the clinical phenotype of TET2 deficiency whereby the lack of compensation by TET3 (low TET3 expression) was associated with poor outcomes of TET2 mutant carriers.
引用
- Gurnari C, Pagliuca S, Guan Y, et al. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2022. PMID: 34768283. doi:10.1182/bloodadvances.2021005418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。